Strata Critical Medical — Q3 2026 Earnings Summary

Strata Critical Medical reported third-quarter 2026 revenue of $74.1 million, representing a 50.3% year-over-year increase driven primarily by clinical acquisitions. The company achieved an adjusted EBITDA of $9.6 million with a margin of 13.0%, while generating $8.6 million in free cash flow. Net loss from continuing operations narrowed to $7.6 million, or 10.3% of revenue, compared to a loss of $9.7 million in the prior year period. Additionally, the company announced a $20 million share repurchase authorization and reiterated its full-year 2026 guidance for revenue between $285 million and $295 million.